SPIMACO approves Dammam Pharma's 50% capital hike
27/12/2018
Argaam
Saudi Pharmaceutical Industries & Medical Appliances Co.’s (SPIMACO) board approved the proposed 50 percent capital increase of its subsidiary, Dammam Pharma to SAR 180 million from SAR 120 million.
SPIMACO will inject SAR 39 million from its own resources in the planned hike, the company said in a statement to Tadawul on Thursday.
The capital increase will be used to finance the Dammam-based plant's working capital requirements, in line with the board's strategy.
The decision is subject to regulatory approvals, SPIMACO said, adding that the related financial impact will be disclosed later on.
Dammam Pharma is 65 percent owned by SPIMACO and 20 percent owned by Arac Healthcare, SPIMACO’s wholly-owned marketing and distribution arm.
Market Indices
TASI
10,878.46
13.89
0.13 %
Quotes
SPIMACO
30.96
0.06
0.19%
About Us
Join Us
Argaam Tools is an advanced tool that provides investors, analysts, research houses, and corporate executives with easy access to a single source for in-depth data on macroeconomy, capital market, sectors, and companies insights.
Argaam.com Copyright © 2026, Argaam Investment, All Rights Reserved
Call Request
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}